Table 1.

Patients' characteristics before TIL therapy

Patient	Gender	At diagnosis			Diagnosis to ACT (y)^*	Prior treatments for stage IV disease
Patient	Gender	Age	Stage	Site of metastasis	Diagnosis to ACT (y)^*	Treatment (not incl. IL-2)	IL-2–based treatment	Response to IL-2 treatment	TTP (mo)
Responders
05-LA	M	39	M1a	SC	2	Surgery	CB	PD	Na
19-NS	M	50	IIb	Na	16	Taxol	CB	PD	Na
03-MG	M	26	Ib	Na	10		CB	PD	Na
06-TS	M	55	III	Na	5		HD bolus	SD	6
09-SD	M	44	IIb	Na	1		CB	PD	Na
13-BS	M	57	IIb	Na	4		CB	SD	7
14-SV	M	69	III	Na	2.3	Surgery	CB	PD	Na
16-SH	M	38	III	Na	2.8	Taxol	CB	PD	Na
18-WR	F	68	III	Na	2.2	Surgery	CB	PR	5
20-TY	M	55	III	Na	3.3	Surgery	CB	CR	5
Median					3.1				5.5
Nonresponders
01-AY	M	51	M1a	SC	5.3		CB	SD	14
07-ZR	M	20	III	Na	1.8		CB	PD	Na
08-RM	F	31	Ia	Na	2.8		CB	PR	2
12-VS	F	36	III	Na	5.5	Surgery	CB	SD	2
02-PE	M	33	III	Na	3	Dacarbacine	CB	PD	Na
04-BA	M	41	III	Na	16.3	Surgery	CB	PR	16
10-BE	F	48	III	Na	4.8		CB	PD	Na
11-KB	M	55	III	Na	2.4		CB	PD	Na
15-SM	M	52	M1c	Liver, bone	Na	Taxol	CB	PD	Na
17-ZD	F	46	Ib	Na	22		CB	PD	Na
Median					4.8				8.0
					P = 0.58				P = 0.47

Abbreviations: TTP, time to progression; CB, chemobiotherapy consisting of IL-2, dacarbazine, and cisplatin; HD, high-dose; Na, not applicable.